FLT3 and acute myeloid leukemia: Although only one-quarter of AML patients harbor FLT3 mutations, the FLT3 receptor is over-expressed on leukemic blast regardless of mutational status (2), and early studies of FLT3 inhibitors observed blast reduction in patients with FLT3-WT disease (19).